Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery Raises $9.9M in Series C Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Horizon Discovery has closed a Series C round of financing, raising £6.25 million ($9.9 million).

The Cambridge, UK-based firm said the funds will be used to improve its core Genesis and X-Man technology platforms, address new markets, and begin targeting therapeutics outside of its initial focus on cancer. Its Genesis technology is a virally-mediated , gene-engineering technology, and its X-Man models are genetically-defined, patient-relevant human cells lines used for modeling disease-causing mutations in cancer patients.

The round was led by European venture capital firm DFL Esprit. Other investors included Roche Venture Fund, Jonathan Milner, and David Evans, who currently is chairman of Immunodiagnostics Systems.

As part of the financing, Horizon appointed DFJ Esprit Partner Nigel Pitchford to its board as investor director and Evans as non-executive director.